Table 2.
Histotyping of 25 cases of lung squamous cell carcinoma and adenocarcinoma by microRNA assays of biopsies
| Biopsy | Resectate | Discordanced | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Sample | Typea | Histologyb (Bp) | Protein markers | Histotype by microRNA assayc (Bm) | Histology (Rp) | Protein markers | Bp–Rp | Bm–Rp |
| A | CC | Carcinoma, poorly diff. | CK−, CK7−, TTF1− | SCC/AC | AC | + | +/− | |
| B | CC | AC with focal SCC, poorly diff. | CK+, CK7+, MUC1+, TTF1− | SCC/SCC | SCC, poorly diff. | CK5/6−, mucin−, TTF1−, | + | −/− |
| C | CF | SCC, poorly diff. | AC/AC | AC, poorly diff. | + | −/− | ||
| D | CF | SCC, moderately diff. | SCC/SCC | SCC, poorly diff. | − | −/− | ||
| E | CC | SCC, moderately diff. | SCC/SCC | SCC, moderately diff. | − | −/− | ||
| F | CF | NSCLC, poorly diff. | CK+, CK7+, TTF1− | SCC/AC | AC, moderately diff. | CK−, CK7−, TTF1− | + | +/− |
| G | BC | SCC | SCC/SCC | SCC, moderately diff. | − | −/− | ||
| H | CF | NSCLC, poorly diff. | AC/AC | AC, moderately diff. | + | −/− | ||
| I | BC | SCC | SCC/SCC | SCC, poorly diff. | − | −/− | ||
| J | BC | SCC | SCC/SCC | SCC, poorly diff. | − | −/− | ||
| K | BF | NSCLC, poorly diff. | SCC/SCC | SCC, moderately diff. | + | −/− | ||
| L | CF | AC, moderately diff. | AC/AC | AC, well diff. | − | −/− | ||
| M | CF | NSCLC | AC/AC | AC, poorly diff. | + | −/− | ||
| N | CF | SCC, poorly diff. | CK+, CK7− | SCC/SCC | SCC, poorly diff. | − | −/− | |
| O | BC | NSCLC, poorly diff. | SCC/SCC | SCC, poorly diff. | + | −/− | ||
| P | BC | NSCLC, poorly diff. | AC/AC | AC, poorly diff. | + | −/− | ||
| Q | BC | SCC | SCC/SCC | SCC, moderately diff. | − | −/− | ||
| R | CF | SCC, moderately diff. | SCC/SCC | SCC, moderately diff. | − | −/− | ||
| S | CF | SCC, moderately diff. | AC/AC | SCC, moderately diff. | − | +/+ | ||
| T | CF | SCC, poorly diff. | SCC/SCC | SCC, moderately diff. | − | −/− | ||
| U | CF | SCC, poorly diff. | SCC/SCC | SCC, moderately diff. | − | −/− | ||
| V | CC | AC, poorly diff. | CK+, CK7−, TTF1+ | SCC/SCC | SCC, moderately diff. | CK5/6+, CK7+, mucin−, P63+, TTF1+ | + | −/− |
| W | BC | SCC, poorly diff. | CK5/6+, P63+ | SCC/SCC | SCC, moderately diff. | CK7+, P63+, TTF1− | − | −/− |
| X | CC | AC, poorly diff. | SCC/SCC | SCC, moderately diff. | + | −/− | ||
| Y | CF | NSCLC, poorly diff. | AC/AC | AC, poorly diff. | + | −/− | ||
BC, bronchoscopic core biopsy; BF, bronchoscopic fine needle aspirate; CC, computerized tomography (CT)-guided core biopsy; CF, CT-guided fine needle aspirate
AC, adenocarcinoma; NSCLC, non–small cell lung cancer; SCC, squamous cell carcinoma. Histology including the grade of differentiation (diff.) was characterized by morphological examination of tissue sections and, for some cases, by the presence (+) or absence (−) of protein markers as assessed by periodic acid-Schiff (mucin) or immunohistochemical (others) staining. CK, cytokeratins as recognized by the AE1/AE3 mouse antibody mix; CK7, etc., cytokeratin 7, etc.; TTF-1, thyroid transcription factor-1
As per the original or modified Lebanony methods; i.e., with Lebanony scores evaluated without or with consideration of miR-375 levels. RT-PCR assays were performed on 0.75 ng RNA.
Presence or absence of discordance between histology diagnosed with routine pathologic examination of biopsy material (Bp) or resected tumor tissue (Rp) and histology identified with microRNA assays of biopsy material (Bm) is designated with a + or −, respectively. For the Bm–Rp comparison, discordance is noted for histotypes identified with the original and modified Lebanony methods.